4:58 PM
 | 
Dec 21, 2018
 |  BC Extra  |  Politics & Policy

FDA could furlough 40% of employees, slow drug reviews under partial shutdown

A lapse of federal funding would mean a partial shutdown at FDA with the potential to slow approvals and advisory committee meetings stretching beyond the length of the impasse.

While negotiations in Washington continue, the possibility for either a short- or long-term budget fix before Friday's midnight deadline is dwindling.

Russell Fortney, acting chief of CDER’s compounding and pharmacy practices branch, told BioCentury much of CDER is funded by user fees, and leftover user fee money will be spent to maintain current advisory committee activities. At least three drugs are slated for...

Read the full 440 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >